✦ LIBER ✦

Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer

✍ Scribed by Laura J. Havrilesky; Robin Pokrzywinski; Dennis Revicki; Robert V. Higgins; Lawrence R. Nycum; Matthew F. Kohler; Andrew Berchuck; Evan R. Myers; Angeles Alvarez Secord

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 206 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26199

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of chemotherapy for patients with r

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer : A cost-effectiveness analysis

✍ Rodney P. Rocconi; Ashley S. Case; J. Michael Straughn Jr.; Jacob M. Estes; Edwa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

Phase II study of belotecan, a camptothe

Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

✍ Chel Hun Choi; Yoo-Young Lee; Tae-Jong Song; Hwang-Shin Park; Min Kyu Kim; Tae-J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Imatinib mesylate in combination with do

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : A Hoosier Oncology Group trial

✍ Daniela Matei; Robert E. Emerson; Jeanne Schilder; Nancy Menning; Lee Ann Baldri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB 👁 1 views